The clinical relevance of pharmacokinetics and drug interactions with anti epileptic drugs by Mifsud, Janet
Issue 15  Summer 2009 Journal of the Malta College of Pharmacy Practice          23
In this paper an overview will be given 
of how knowledge of pharmacokinetic 
mechanisms determines which 
pharmacokinetic characteristics an AED 
should have. Various clinical factors such 
as age, underlying physiological conditions 
and drug interactions will also affect the 
pharmacokinetics and efficacy of AED 
medication.  It will be shown how by 
anticipating changes in pharmacokinetics 
due to possible drug interactions, or 
alterations in one of the pharmacokinetic 
parameters, adverse effects and breakthrough 
seizures may be averted and aid in the 
choice of optimal AED therapy for each 
patient.
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Introduction 
Data from the World Health Organization 
indicate that as many as 1 in 20 people may 
have an epileptic seizure during their lives 
and that at least 1 in 200 people will have 
epilepsy.1 No single antiepileptic drug (AED) 
is appropriate in all clinical situations and 
epileptologists agree that proper seizure 
diagnosis and classification is important 
in individualizing pharmacotherapy.2 
Therapeutic decisions should be made on 
a variety of specific factors such as seizure 
type(s), onset of drug effect, the presence of 
renal or hepatic disease, possibility of drug 
or disease state interactions, the possibility 
of pregnancy, the age of the patient, 
adherence to therapy issues, substance 
abuse history, and prior history of AED use. 
Many of the new drugs are approved only for 
adjunctive use; thus, polypharmacy and drug 
interactions should also be considered.3  
Pharmacokinetics has an important 
role to play in the clinical use of AED 
therapy.4 The term pharmacokinetics includes 
the quantitative assessment of changes 
of drug concentrations over time as a 
function of the absorption, distribution, 
metabolism and elimination processes. 
These processes determine drug plasma 
concentrations and in turn the drug plasma 
therapeutic ranges.5  Pharmacokinetics 
is thus important in estimating the drug 
dosage regimens necessary to achieve 
drug plasma concentrations and predicting 
the time to steady-state concentration 
that will control seizures without causing 
unacceptable toxicity.6  In this paper an 
overview will be given of how a knowledge of 
pharmacokinetic mechanisms will determine 
the ideal pharmacokinetic characteristics of 
an AED, and an appreciation of the relevance 
of parameters such as bioavailability, 
steady-state concentrations, protein-binding, 
metabolism and clearance in AED therapy.4,7
Various clinical factors such as age, 
underlying physiological conditions and drug 
interactions will also affect efficacy of AED 
medication.2 Interaction among AEDs, and 
between AEDs and other classes of drugs, 
can result in undesirable drug levels and 
thus difficulty in achieving seizure control.5 
By anticipating possible drug interactions 
or alterations in metabolism, adverse 
effects and breakthrough seizures may 
be averted.  An awareness of AED clinical 
pharmacokinetics will thus aid the choice of 
an appropriate drug and permits the design 
of an optimal dosage schedule for each 
patient.8
What is Pharmacokinetics?
Pharmacokinetics is the quantitative 
description of what happens to a drug 
when it enters the body, and includes the 
processes of drug absorption, distribution, 
metabolism and elimination / excretion - 
ADME and how these processes affect the 
drug plasma concentrations obtained.9











No single antiepileptic drug (AED) is appropriate in all clinical 
situations and therapeutic decisions on the selection of the 
appropriate AED should be made on a variety of specific factors. 
Pharmacokinetics has an important role to play in the clinical 
practice of antiepileptic drug therapy, as it is important in estimating 
individualised drug dosage regimens necessary to achieve drug plasma 
concentrations without causing unacceptable toxicity.  
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Pharmacokinetics (PK) briefly is what 
the body is doing to the drug; while 
pharmacodynamics (PD) is what the drug is 
doing to the body.9 
Pharmacodynamic effects include both 
wanted and unwanted drug pharmacological 
effects. The underlying assumption is that 
monitoring drug plasma concentrations is 
useful since they reflect drug concentration 
at the receptor site, and thus being able 
to predict drug plasma concentrations is 
important since it will have a bearing on 
the dose required to obtain therapeutic drug 
concentrations.  The individualisation of the 
drug doses needed for specific patients as a 
result of varying pharmacokinetics is called 
clinical pharmacokinetics.  Pharmacokinetics 
is useful because the basic principles are the 
same for all drugs.7 Figure 1. 
Plasma concentration time curves are a 
snap shot of what happens to the drug in the 
body.  If we had to mathematically represent 
what is happening a plasma concentration 
time curve is obtained.5
Figure 2 represents what happens to a 
single dose of drug when given by any non-
iv route.6 The graph may be divided into 3 
phases:
A:  an initial absorption phase
B:  a distribution phase
C:  an elimination phase, which is linear if 
the plasma concentration axis is logged.
This mathematical manipulation helps 





•	 T	1/2  half life of the drug
•	 Cl		 drug	clearance	–	generally	renal	
  or hepatic
•	 F		 bioavailability	of	the	drug
These parameters can then be inputted 
into mathematical formulae that allow 
the estimation of the best dose of a drug 
in a specific patient depending on the 
pharmacokinetic parameters in that patient.7
If multiple doses have to be administered 
the graph would change as represented in 
Figure 3. The plasma concentrations increase 
until, at the certain point, the minimum 
and maximum plasma concentrations remain 
constant i.e. steady state is achieved.6  
This usually takes about five half-lives and 
depends on the volume of distribution 
and clearance of the drug.  Ideally plasma 
concentrations at steady state should be 
within the therapeutic index for the drug i.e. 
the concentration that achieves therapeutic 
effect, without going subtherapeutic or toxic 
levels, in order to ensure that the drug is 
exerting its effect maximally.7 Figure 3. 
The pharmacokinetics of a drug are 
estimated in the first phases of drug 












interactions  with no cytochrome-2D6 
metabolism
•	 Have	no	active	metabolites	and	no	
genetic polymorphism in metabolic 
pathways.9,10
Absorption 
Absorption is the entry of drug molecules 
into the systemic circulation via the mucous 
membranes of the gut or lungs, via the 
skin, or from the site of an injection. Most 
AEDs are administered orally since epilepsy 
is a chronic condition, and thus this will 
enhance patient compliance.7 AEDs also 
exist as formulations that are available 
for intravenous, intramuscular or rectal 
administration.9 Thus rectal administration 
e.g. with rectal diazepam is useful as it 
has been shown to terminate repetitive 
seizures in children with epilepsy and 
other disabilities, and can be administered 
by family members at home.2 Intravenous 
administration e.g. phenytoin, phenobar-
bital, diazepam, lorazepam, levetiracetam 
and valproic acid are generally used for 
emergencies such as status epilepticus since 
the lengthy absorption phase is avoided.11  
With oral formulations, the rate of 
absorption and bioavailability varies widely 
by drug, formulation, patient characteristics, 
concomitant drugs, and food.  Absorption 
can also be altered by drug interactions.12 
Absorption depends also on the excipents 
that make up the formulation, and in 
fact differences between AEDs from 
different manufacturers may result in 
differences in bioavailability of the active 
drug.  Thus changes in drug supply may 
result in breakthrough seizures.2 Calcium 
containing antacids may interfere with 
phenytoin, phenobarbital, carbamazepine, 
and gabapentin absorption by decreasing 
the acidity of the stomach and also by the 
formation of insoluble complexes that cannot 
be absorbed absorption.11 Gabapentin (but 
not its chemical relative, pregabalin) is 
absorbed by a saturable amino acid transport 
system and thus larger doses will cause 
saturation.13
Of particular concern is the issue of 
concomitant administration of an AED 
with an enteral nutrition supplement. 
Concomitant administration of phenytoin 
with these nutritional formulations can result 
in marked reductions in oral bioavailablilty 
of this drug and it is commonly suggested 
that the administration of phenytoin and 
enteral feedings be separated by at least 
2 hours.11 Unfortunately, this may not be 
practical, particularly for patients requiring 
continuous feedings. Alternatively, clinicians 
can overcome this interaction by simply 
increasing the phenytoin dosage, and using 
serum drug concentrations as a guide.9  
Co-administration of the newer AEDs such 
as valproate, levetiracetam, lamotrigine or 
gabapentin with enteral feeding supplements 
does not appear to result in significant 
declines in AED serum concentrations.13
Distribution 
Following absorption into the general 
circulation, the drug is distributed 
throughout the body. The volume of 
Figure 2. Plasma concentration time curve following a single dose not given by the IV route6
A-  mostly absorption; depends on ka, F
B - mostly distribution; affected by %fu, Vd
C-  mostly elimination (renal/hepatic); Cl, t ½ 
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distribution is a virtual volume that gives 
an indication of the extent of distribution of 
the drug to the various tissues.  It may vary 
if the patient has liver or cardiac problems or 
if the patient is pregnant.7
Drugs are generally protein bound, to 
a variable extent in the plasma, however 
this process is reversible. It is the unbound 
drug that crosses membranes and is thus 
responsible for the drug’s action (both 
therapeutic and toxic), so changes in 
unbound, or free serum concentrations 
have the potential to cause unanticipated 
effects.6 Drug-protein binding displacement 
interactions can occur when two highly 
protein	bound	agents	(>90%)	are	
administered together and compete for 
a limited number of binding sites.11 In 
most cases, protein binding displacement 
interactions are transient clinical 
events, however if only total drug serum 
concentrations are being monitored, this 
may lead to misinterpretation of plasma drug 
levels.2
Among the AEDs, the potential for 
protein-binding interactions is greatest 
for phenytoin and valproic acid. Both 
phenytoin, and valproic acid are extensively 
bound	to	plasma	proteins	(>90%).		Valproic	
acid is also an inhibitor of cytochrome 
P4502C19, one of the enzymes responsible 
for phenytoin metabolism.11 When these 
two agents are co-adminis tered, unbound 
phenytoin concentrations are higher than 
expected and total concen trations are 
lower.9 In this setting, the clinician should 
consider monitoring both unbound and 
total phenytoin concentrations.2 The most 
important implication of this interaction 
is that in the presence of valproic acid 
the “therapeutic” range of total plasma 
phenytoin concentrations is shifted towards 
lower values.12 With the exception of 
tiagabine (96% protein bound) an advantage 
of the newer generation AEDs is that they are 
not extensively protein bound, and therefore 
in this group these types of pharmacokinetic 
interactions are not likely.3
Metabolism 
Enzymatic biotransformation and 
metabolism is the principal determinant of 
the pharmacokinetic properties of most AEDs, 
although some drugs are excreted by the 
kidneys predominantly as unchanged drug.2 
Most AEDs exhibit linear enzyme kinetics, in 
which clearance remains constant so changes 
in daily dose lead to proportional changes 
in serum concentration. It is to be noted 
that some metabolites are themselves active 
(carbamazepine, oxcarbazepine, primidone).7 
The metabolic pathways of AEDs 
can vary, however, most metabolism is 
achieved via oxidative metabolism and/
or glucuronidation.9 Oxidative metabolism 
occurs via the cytochrome P450 (CYP) 
isoenzyme system.  This system consists 
of three main families of enzymes: CYP1, 
CYP2, and CYP3.  There are seven primary 
isoenzymes that are involved in the 
metabolism of most drugs: CYP1A2, CYP2A6, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4.  Of these, those commonly involved 
with metabolism of AEDs include CYP2C9, 
CYP2C19, and CYP3A4.14  Another important 
metabolic pathway for several AEDs including 
valproic acid, lorazepam and lamotrigine 
is conjugation via the enzyme uridine 
diphosphate glucuronosyltransferase (UGT).13 
By far the most important 
pharmacokinetic interactions with AEDs are 
those related to induction or inhibition of 
drug metabolism.6 
Enzyme induction is due to increased 
synthesis of drug-metabolising isoenzymes 
in the liver and in other tissues and may 
be caused by carbamazepine, phenytoin, 
and barbiturates. If the affected drug has 
an active metabolite, enzyme induction can 
result in increased metabolite concentration 
and possible toxicity due to the metabolite.2 
Enzyme inhibition is the phenomenon 
by which a drug or its metabolite blocks the 
activity of one or more drug-metabolising 
enzymes, which results in a decrease in the 
rate of metabolism of the affected drug. 
This, in turn, will lead to high plasma 
concentrations of the drug and, possibly, 
clinical toxicity.14
In some cases, AED-AED interactions are 
bi-directional. In other words, both drugs 
impact the pharmacokinetics of the other. In 
general, enzyme inducers decrease the serum 
concentrations of other drugs metabolized by 
the same isoenzyme and enzyme inhibitors 
have the opposite affect.8 The bi-directional 
interaction between carbamazepine and 
valproate is one common example. In this 
setting, valproate can inhibit the enzyme 
epoxide hydrolase, which is responsible for 
the metabolism of the active metabolite 
of carbamazepine, carbamazepine-
epoxide. Elevated carbamazepine -epoxide 
concentrations have been associated 
Figure 4. Changes in phenytoin plasma concentration after increase in dose 
due to non linear kinetics 6
Figure 3. Plasma concentration time curve following multiple doses given by the non IV route6
Cp
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with increased neurotoxicity. In addition 
carbamazepine can also significantly increase 
the metabolism of valproate, necessitating 
larger doses of this medication.2
Other interactions may be of benefit 
in certain cases e.g. the synergistic effect 
of valproic acid and lamotrigine which are 
metabo lized by (UDP)-glucuronyltranferase.14
Renal elimination
Elimination is the removal of drug 
molecules from the body, usually by excretion 
of the parent drug or metabolites through 
the kidneys.  Drug elimination rate is usually 
expressed as the biological half-life and is 
defined as the time required for the serum 
concentration to decrease by 50% following 
absorption and distribution. The half-
life also determines the dosing frequency 
required for a drug to be maintained at a 
steady state in the serum.6
Drugs that undergo extensive renal 
elimination in unchanged form may be 
susceptible to interactions affecting the 
excretion process, particularly when it 
involves active transport mechanisms or 
when the ionised state of the drug is highly 
sensitive to changes in urine pH, e.g. agents 
that cause alkalisation of urine increase the 
elimination of phenobarbital by reducing the 
reabsorption of this acidic drug from renal 
tubuli.7
Particular mention should be made 
of phenytoin since it has unusual 
pharmacokinetics which are saturable or 
non-linear.6 In other words, unlike drugs 
that display linear elimination kinetics 
(where changes in serum concentration 
are proportional to dose), phenytoin 
concentrations will show disproportionate 
changes in concentration following dose 
adjustment. In clinical terms, this suggests 
that dose adjustments with this medication 
be small since increasing the dose by 50% 
could increase the plasma concentration four 
fold. 2 
Some AEDs eg gabapentin and pregabalin 
are only eliminated  renally and do not 
undergo any metabolism.7
Drug interactions: impact of AED 
treatment on commonly used 
medical therapies
As has been explained, the occurrence 
of pharmacokinetic interactions has the 
potential to substantially complicate the 
management of the patient with epilepsy. 
This may be particularly true when dealing 
with the elderly patient.8 In treating the 
older patient with epilepsy, it is important 
for the clinician to recognize that treatment 
with AEDs, particularly the older enzyme 
inducing AEDs such as phenobarbital, 
phenytoin and carbamazepine15, may 
complicate the management of other co-
morbid disorders such as cardiovascular 
disease and affective disorders which more 
commonly occur in the group of patients.12 
The following sections provide an overview of 
potentially clinically meaningful interactions 
that are likely to be encountered in practice. 
Tables 1-2.
Interactions of AEDs with drugs used in 
the treatment of hypertension
The pharmacologic management 
of hypertension may require multiple 
antihypertensive drugs of differing classes. 
Several commonly used antihypertensive 
medications may be susceptible to 
interactions with enzyme-inducing 
antiepileptic drugs.16 For example, lipophilic 
beta antagonists such as propranolol and 
metoprolol are extensively metabolized 
by several isozymes of the CYP system. 
Therefore, larger doses of these medications 
might be required in patients receiving 
AEDs, which would be expected to increase 
their rate of clearance.2 Conversely, fewer 
potential interactions would be expected 
with the hydrophilic beta antagonists, such 
as atenolol and labetalol, which are primarily 
renally excreted.15
Another commonly used class of 
antihypertensive medication are the 
calcium channel antagonists. Drugs such 
as felodipine, nifedipine, nicardipine, 
amlodipine, and nimodipine are members 
of the dihydropyridine class of agents, and 
these agents are extensively metabolized 
by CYP3A4. Concomitant treatment with 
enzyme inducers such as carbamazepine 
and phenytoin can result in substantial 
reductions in the oral bioavailability of 
these medications.13 Other commonly used 
antihypertensive drugs such as diuretics 
and ACE inhibitors are not extensively 
metabolized, and thus would not be expected 
to interact with AEDs.
Interactions of AEDs with drugs used in 
the treatment of lipid disorders
HMG-CoA reductase inhibitors 
(“statins”) are among the most commonly 
prescribed lipid-lowering medications. 
Lovastatin, simvastatin, and atorvastatin 
are metabolized extensively via CYP3A4. 
Simvastatin and atorvastatin are also 
metabolized via glucuronidation (UGT 
1A3) in both the gut and the liver. 
Fluvastatin is metabolized by CYP2C9. 
All of these agents would therefore be 
expected to be susceptible to interaction 
with enzyme inducing AEDs.15 Indeed, one 
pharmacokinetic study suggested that 
systemic exposure to simvastatin may be 
reduced by nearly 80% in patients receiving 
carbamazepine. Alternatively, other related 
drugs such as pravastatin and rosuvastatin 
are not extensively metabolized, so 
significant pharmacokinetic interactions 
with AEDs would not be anticipated.16  
Among the newer AEDs, only topiramate 
and oxcarbazepine appear to display modest 
CYP3A4 inducing potential and thus the 
potential for interactions between these 
lipid-lowering drugs and AEDS is expected 
to be minimal. Unfortunately, at present no 
studies have been performed to document 
this.11
Interactions of AEDs with anticoagulants
Warfarin is administered as a racemic 
mixture of R- and S- enantiomers. 
S-warfarin is exclusively metabolized via 
CYP2C9, while R-warfarin is metabolized 
by several CYP isozymes including CYP1A2 
and CYP3A4.2 Since the S- enantiomer of 
warfarin is considerably more active than 
the R- enantiomer, interactions involving 
CYP2C9 are far more likely to have important 
clinical consequences. Carbamazepine 
and phenobarbital can in fact reduce the 
anticoagulant effect by increasing warfarin 
metabolism.16
The interaction between warfarin and 
phenytoin is far more complex.  Initially, 
the coadministration of phenytoin may 
result in an increase in anticoagulant 
effect, possibly due to the combined 
effect of protein-binding displacement and 
competitive inhibition of CYP2C92, causing a 
seemingly “paradoxical” anticoagulant effect 
(i.e. increased prothrombin time, INR). In 
the long term however, enzyme induction 
will probably lead to increased warfarin 
metabolism, necessitating increased warfarin 
doses.11
Clearly, in patients receiving warfarin 
and AED treatment, careful monitoring of 
international normalized ratios is crucial. 
Whenever possible, this drug combination 
should be avoided. Newer AEDS such as 
gabapentin, pregabalin, lamotrigine, 
levetiracetam and zonisamide do not appear 
to interact with warfarin, and may be 
safer (from a drug interaction viewpoint) 
alternatives.15,16
Interactions of AEDs with drugs used in 
the treatment of depression
Most psychotropic drugs are metabolized 
by one or more of the CYP isozymes.14 
Therefore, co-medication with an inducing 
drug would be expected to increase the 
metabolism, and therefore systemic clearance 
of these medications. Serum concentrations 
of tricyclic antidepressants such as 
amitriptyline, nortriptyline, imipramine, and 
desipramine, as well as nontricyclics such as 
sertraline, paroxetine, mianserin, citalopram, 
and nefazodone, would be expected to be 
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reduced in patients receiving enzyme inducers.16 
Conversely, treatment with some SSRI 
compounds has the potential to impact AED 
pharmacokinetics. For example, fluoxetine 
has been shown to inhibit several CYP 
isozymes, and concomitant treatment 
with phenytoin or carbamazepine may 
result in elevated serum concentrations of 
those agents.2 In contrast to the inducers, 
valproate can inhibit certain CYP and UGT 
enzymes and may cause significant increases 
(50%-60%) in serum concentrations of 
antidepressants such as amitriptyline and 
nortriptyline.14 In some patients, this 
increase may be sufficient to result in the 
emergence of adverse effects.  Given that 
many of the newer AEDs are, in general, 
less likely to interact with the CYP isozyme 
system the likelihood of meaningful 
pharmacokinetic interactions is also reduced.11
 
Patient influences on drug 
pharmacokinetics 
Various physiological and pathological 




Drug metabolism and disposition in 
children can differ significantly from that 
in adults.17 Beyond the neonatal period, 
when protein binding and drug metabolic 
rates are low, children usually have faster 
drug elimination rates and reduced serum 
half-lives relative to adults.2 Some children 
require almost twice the adult mg/kg dosage, 
particularly if combination therapy with 
enzyme-inducers is employed.17 
Despite frequent drug administration, 
large swings in peak-to-peak concentrations 
are possible, especially in young children, 
because of their fast elimination rates.18 
Solid oral dosage forms overcome this 
problem by providing a longer absorption 
phase that reduces peak and increases 
trough concentrations. Crushed tablets are 
preferable to liquids in younger children for 
similar reasons. Rapid gastrointestinal transit 
times in children may, however, impede 
absorption.17 In children, drug metabolism 
and disposition can differ significantly from 
that in adults. Beyond the neonatal period, 
when protein binding and drug metabolic 
rates are low, children usually have faster 
drug elimination rates and reduced serum 
half-lives relative to adults.8 Some children 
require almost twice the adult mg/kg dosage, 
particularly if combination therapy with 
enzyme-inducers is employed. Furthermore, 
because of shorter paediatric half-lives, 
most AEDs require at least three times daily 
administration in children 1-10 years of age.13
Elderly
In the elderly, AEDs should usually be 
started at a lower dose and increased at 
a slower rate than in younger patients.18 
Elimination of many drugs is slower in the 
elderly, mainly because of reduced hepatic 
and renal blood flow, which lengthens drug 
half-life above published values based on 
young adults. In addition, albumin levels 
fall with age; this increases the free fraction 
of drugs that are highly protein bound, thus 
increasing risk of toxicity, especially for 
highly protein-bound drugs.17 Regarding the 
elderly, elimination of many drugs is slower, 
mainly because of reduced hepatic and renal 
blood flow, which lengthens drug half-life 
above published values based on young 
adults.2 In addition, albumin levels fall with 
age and this increases the free fraction of 
drugs that are highly protein bound, thus 
increasing risk of toxicity, especially for 
highly protein-bound drugs. Further, older 
people are often more sensitive to drug 
effects at a given free level. In the elderly, 
AEDs should usually be started at a lower 
dose and increased at a slower rate than in 
younger patients.8 
Pregnancy
Pregnancy increases the volume of 
distribution and the rate of drug metabolism, 
and decreases protein binding. For most 
AEDs, the optimal dose increases as 
pregnancy progresses.2 It is also noteworthy 
that in cases of pregnancy, the volume of 
distribution and the rate of drug metabolism 
Table 1. Effect of older AEDs on newer AEDs3,8,16
 gabapentin/   lamo-      levetir-     zonisa-
 pregabalin     trigine   topiramate   tiagabine    acetam     mide   Ox-carbazepine
  phenytoin none i i i   none    i  mhd1 slt
  carbamazepine none i i i   none    i  mhd slt
  valproic acid none i none none   none    none  none
  phenobarbital none i i i   none    i  mhd slt
  primidone none i i i   none    i  mhd slt
  1: Monohydroxy-derivative
 phenytoin carbamazepine valproic acid phenobarbital  primidone
  Gabapentin none none none none none
  Pregabalin
  lamotrigine none none i 25% none none
  topiramate may h none none none none
  tiagabine none none none none none
  zonisamide none none none none none
  levetiracetam none none none none none
  oxcarbazepine none none none none none
Table 2. Effect of newer AEDs on older AEDs3,8,16
Drug Absorption Elimination Half life Protein Causes 
   (Hours) binding interactions
Carbamazepine 80% 100% hepatic 6 -12 75-80% yes
Valproic Acid 100% 90% hepatic 12-20 85-95%;  yes
Phenobarbitone 100% 75% hepatic 17-124  50% yes
Phenytoin 95%, 100% hepatic  12-60 70-95%  yes
Clobazebam 90%; 100% 10-50 83% yes
Gabapentin	 <	60%		 100%	renal	 5-8	 0%	 no
Flebamate well absorbed 40-49% renal 13-30 20-25% yes
Lamotrigine 98% 100% hepatic 18-30 55% yes
Levetiracetam	 100%	 66%	renal	 4-8	 <10%	 no
Oxcarbazepine (MHD) 100% 100% hepatic 5-11 40% yes
Pregabilin 90% 90% renal no
Tiagabine 96%.  97% hepatic 5-13 96% no
Topiramate	 >80%;	 30-55%	renal	 18-30		 15%	 yes
Zonisamide 80-100% 50-70% hepatic 50-80 40-60%. no 
Table 3. Summary of PK characteristics of AEDS3,4,8,16
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•	 Pharmacokinetics	is	the	quantitative	description	of	what	happens	to	a	drug	when	it	
enters the body, and is important in estimating the drug dosage regimens necessary to 
achieve drug plasma concentrations without causing unacceptable toxicity. 
•	 Knowledge	of	pharmacokinetic	mechanisms	will	determine	the	ideal	pharmacokinetic	
characteristics of an AED, and an appreciation of the relevance of parameters such as 
bioavailability, steady-state concentrations, protein-binding, metabolism and clearance 
in AED therapy.
•	 Various	clinical	factors	such	as	age,	underlying	physiological	conditions	and	drug	
interactions will also affect efficacy of AED medication. 
•	 Interaction	among	AEDs,	and	between	AEDs	and	other	classes	of	drugs,	can	result	
in undesirable drug levels and thus difficulty in achieving seizure control. By 
anticipating possible drug interactions or alterations in metabolism, adverse effects and 
breakthrough seizures may be averted.  
•	 An	awareness	of	AED	clinical	pharmacokinetics	will	thus	aid	the	choice	of	an	appropriate	
drug and permits the design of an optimal dosage schedule for each patient.
Practice points
are increased whereas protein binding is 
decreased. For most AEDs, the optimal dose 
increases as pregnancy progresses.19
Others
Fever can increase the metabolic rate, 
resulting in more rapid drug elimination and 
lower serum con centrations. Febrile illnesses 
may also elevate serum proteins that bind 
AEDs, resulting in decreased free levels.2 
Severe hepatic disease impairs 
metabolism, increasing serum levels and risk 
of toxicity of many drugs. However, complex 
interactions among hepatic blood flow, 
biliary excretion, and hepatocellular function 
make the net effect of hepatic disease on 
drug levels difficult to predict.18
Renal disease reduces elimination of 
some drugs such as gabapentin. In chronic 
renal disease where there is protein loss, one 
can commonly see a higher free fraction of 
highly protein bound AEDs which then are 
more susceptible to elimination lower serum 
concentration of the drug. More frequent 
doses may need to be given. Effects of 
dialysis differ among AEDs. Some, such as 
phenobarbital, are significantly removed.2 
Table 3.
PK parameters and drug interactions of 
AEDs: which way to go?
Determining the pharmacokinetics and 
the avoidance of durg-drug interactions 
are useful selection criteria for AED 
selection.  Indeed, the characterization of 
the clinical pharmacokinetic profile of a new 
antiepileptic drug is an integral and early 
component of drug development.9
Consequently, pharmacokinetic 
considerations are especially relevant with 
antiepileptic drugs for several reasons.9 
Patients with epilepsy generally require 
chronic therapy, and, therefore, a dosing 
strategy that enhances compliance is 
essential. Also, many patients will be 
prescribed two or more antiepileptic drugs, 
often times at the highest possible doses.8 
Additionally, all patients with chronic 
epilepsy can be expected to develop during 
their lifetime concomitant nonepilepsy-
related diseases that require additional drug 
therapy, increasing the potential for drug 
interactions and toxicity. Thus, it is desirable 
that the drugs do not cause interactions that 
can precipitate toxicity.13 
Finally, it is important to recognize that 
drug interactions are not a “one-way street”. 
Interactions can be bi-directional, meaning 
that two drugs can influence each other.18 
In addition, another important concept is 
that drug interactions may occur not only 
when an inducer or inhibitor is added to 
a patient’s medication regimen, but also 
when the inducing (e.g. carbamazepine) or 
inhibiting (e.g. valproate) agent is removed.
 Removal of an enzyme-inducing drug 
will result in “deinduction,” and if doses 
are not adjusted, serum concentrations of 
many metabolized concomitant drugs may 
increase.2 Loss of enzyme induction can 
occur with days to several weeks following 
discontinuation of the inducing drug. Given 
that it will take about five half-lives for the 
previously induced medication to reach a 
new steady-state level, these de-induction 
interactions may have an insidious onset.10
Thus good knowledge of the 
pharmacokinetic mechanisms of the various 
AEDs will significantly aid the decision of 
which dosing strategy is the most efficient 
and enhance clinical therapy of AEDs.
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